Form 4: Fulgent Genetics CSO Executes Tax-Related Stock Sale
Statement of Changes in Beneficial Ownership
Chief Scientific Officer Hanlin Gao sold 1,688 shares of Fulgent Genetics to cover tax obligations related to RSU vesting.
Summary
- Chief Scientific Officer Hanlin Gao sold 1,688 shares of common stock on June 2, 2026.
- The shares were sold at a weighted-average price of $17.8855 per share.
- The transaction was executed to satisfy tax withholding obligations resulting from the vesting of restricted stock units (RSUs).
- Following the transaction, the reporting person retains beneficial ownership of 990,374 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale is purely administrative and related to tax obligations rather than a strategic divestment.
Positives
- The sale was non-discretionary, specifically executed to cover tax liabilities rather than reflecting a change in sentiment regarding company prospects.
Negatives
- The transaction represents a reduction in the insider's direct equity stake in the company.
Risks
- Insider selling, even for tax purposes, can sometimes be perceived negatively by retail investors despite the routine nature of the transaction.
Future Outlook
No forward-looking guidance or strategic outlook was provided in this filing.
Industry Context
StockSavvy.ai notes that routine 'sell-to-cover' transactions by C-suite executives are standard practice in the biotechnology sector to manage tax liabilities associated with equity-based compensation plans and generally do not signal a lack of confidence in the issuer's long-term strategy.
Comparison to Industry Standards
- The transaction aligns with standard corporate governance practices for executive compensation management.
- The use of a weighted-average price for tax-related sales is consistent with reporting requirements for companies like Exact Sciences or Guardant Health.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was a routine tax-related sell-to-cover event.
Key Dates
| Date | Description |
|---|---|
| 02/25/2025 | Original grant date of the restricted stock units. |
| 02/27/2025 | Date the original RSU grant was reported to the SEC. |
| 06/02/2026 | Date of the reported stock sale transaction. |
| 06/03/2026 | Date the Form 4 was filed with the SEC. |
Keywords
Fulgent Genetics, FLGT, Insider Trading, Form 4, Chief Scientific Officer, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.